The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.

Levodopa, a prodrug of dopamine, remains to be one of the main drugs in the treatment of Parkinson's disease. All current levodopa products are formulated with aromatic amino acid decarboxylase inhibitors such as carbidopa or benserazide to prevent the metabolism of levodopa in the gastrointestinal tract and systemic circulation. Levodopa pharmacokinetic profiles remain unchanged after multiple doses, and are similar between healthy volunteers and patients and among patients at different stages of disease. Entacapone inhibits the metabolism of levodopa therefore increases the area under the plasma concentration-time profile of levodopa; however, it may decrease the initial absorption rate of levodopa in some patients probably due to competitive absorption. Food appears to affect the absorption of levodopa, but its effects vary with formulations. The results of positron emission tomography study suggest that a high protein diet may compete with the uptake of levodopa into the brain, therefore, may result in reduced levodopa effects. Since infusion studies demonstrated that it is beneficial to maintain stable plasma concentrations of levodopa, controlled-release formulations have been designed to provide prolonged absorption of levodopa. However, subsequent pharmacokinetic and pharmacodynamic studies demonstrated that a threshold concentration of levodopa appears to be necessary to switch patients "on". Once patients are turned "on", the duration of levodopa effects may be correlated with plasma concentration of levodopa. As such, more recent studies have demonstrated significant clinical benefits such as shorter time to "on" and longer duration of "on" when combining the immediate- and controlled-release levodopa products as compared to controlled-release levodopa products. Given these findings, it is important for physicians to understand the relationship between the pharmacokinetics and pharmacodynamics of levodopa in order to provide dosage regimens that meet patient needs. The pharmacokinetics and pharmacodynamics data of levodopa reported in the literature are reviewed here.

[1]  L. Watson,et al.  Inhibition of dopa decarboxylase by the hydrazino analog of α-methyldopa , 1962 .

[2]  A. Pletscher,et al.  Distribution and metabolism of DL-3,4-dihydroxy[2-14C]-phenylalanine in rat tissues. , 1964, The Biochemical journal.

[3]  A. Pletscher,et al.  Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine , 1969, The Journal of pharmacy and pharmacology.

[4]  J. Gaillard,et al.  [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)]. , 1969, Neurologia, neurocirugia, psiquiatria.

[5]  V. J. Lotti,et al.  Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. , 1970, The Journal of pharmacology and experimental therapeutics.

[6]  J. Bianchine,et al.  Metabolic Studies and Clinical Observations During L-Dopa Treatment of Parkinson's Disease , 1970, British medical journal.

[7]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[8]  L. Rivera-calimlim,et al.  Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays. , 1971, Archives of neurology.

[9]  M. Goodall,et al.  Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects. , 1972, Biochemical pharmacology.

[10]  F. Messiha,et al.  Peripheral aromatic l‐amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of l‐2‐14C‐dopa , 1972, Clinical pharmacology and therapeutics.

[11]  C. Andrews,et al.  Catecholamine Metabolism During Oral Administration of Levodopa: Effects of the Medication in Parkinson's Disease , 1972 .

[12]  R. Tissot,et al.  Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats , 1972, The Journal of pharmacy and pharmacology.

[13]  R. Rosenfield,et al.  The levodopa test of growth hormone reserve in children. , 1973, American journal of diseases of children.

[14]  M. E. Jaffe,et al.  METABOLISM OF CARBIDOPA [L-(-)-α-HYDRAZINO-3,4-DIHYDROXY-α-METHYLHYDROCINNAMIC ACID MONOHYDRATE], AN AROMATIC AMINO ACID DECARBOXYLASE INHIBITOR, IN THE RAT, DOG, RHESUS MONKEY, AND MAN , 1974 .

[15]  D. Wade,et al.  Metoclopramide, gastric emptying and L-dopa absorption. , 1974, Australian and New Zealand journal of medicine.

[16]  G. C. Cotzias,et al.  Protein intake and treatment of Parkinson's disease with levodopa. , 1975, The New England journal of medicine.

[17]  Further studies on the metabolism of carbidopa, (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate, in the human, Rhesus monkey, dog, and rat. , 1975 .

[18]  K. Sasahara,et al.  Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients. , 1980, Journal of pharmaceutical sciences.

[19]  K. Sasahara,et al.  Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. , 1980, Journal of pharmaceutical sciences.

[20]  P. Emson,et al.  Enzymes Related to Monoamine Transmitter Metabolism in Brain Microvessels , 1980, Journal of neurochemistry.

[21]  M. Hoehn Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. , 1980, Archives of neurology.

[22]  J. Nutt,et al.  Pharmacokinetics of levodopa. , 1984, Clinical neuropharmacology.

[23]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[24]  S. Yorifuji,et al.  Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson disease , 1984, Journal of the Neurological Sciences.

[25]  S. Kaakkola,et al.  The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa , 1985, Acta neurologica Scandinavica.

[26]  R. Shelton,et al.  Metabolism of carbidopa to alphamethyldopamine and alphamethylnorepinephrine in rats , 1985 .

[27]  P. Martínez-Martín,et al.  Carbidopa dosage modifies L‐DOPA induced side effects and blood levels of L‐DOPA and other amino acids in advanced parkinsonism , 1985, Acta neurologica Scandinavica.

[28]  J. Nutt,et al.  The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism , 1985, Annals of neurology.

[29]  F. Mcdowell,et al.  Effect of supplemental carbidopa on bioavailability of L-dopa. , 1986 .

[30]  J. Nutt,et al.  Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients , 1986, Neurology.

[31]  Richard S. J. Frackowiak,et al.  Inhibition of L‐{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography , 1986, Annals of neurology.

[32]  M. Contin,et al.  Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. , 1987, Clinical neuropharmacology.

[33]  J. Bartko,et al.  Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.

[34]  K C Yeh,et al.  Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. , 1989, Neurology.

[35]  J. G. Nutt,et al.  Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease , 1989, Neurology.

[36]  W. Woodward,et al.  The effect of dietary protein on the efficacy of L‐dopa , 1989, Neurology.

[37]  A. Lees,et al.  The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[38]  A G Renwick,et al.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. , 1989, British journal of clinical pharmacology.

[39]  I. Heuser,et al.  Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease , 1990, Annals of neurology.

[40]  S. Coughlin,et al.  Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. , 1991, Archives of neurology.

[41]  A G Renwick,et al.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. , 1991, British journal of clinical pharmacology.

[42]  J. Nutt,et al.  Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. , 1992, Archives of neurology.

[43]  M. Karlsson,et al.  The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. , 1993, Clinical neuropharmacology.

[44]  P. Cortelli,et al.  Longitudinal monitoring of the levodopa concentration‐effect relationship in Parkinson's disease , 1994, Neurology.

[45]  C. Marsden,et al.  Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. , 1994, Clinical neuropharmacology.

[46]  N H Holford,et al.  The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.

[47]  M. Memmi,et al.  Concentrations of L-dopa in plasma and plasma ultrafiltrates. , 1996, Journal of pharmaceutical and biomedical analysis.

[48]  J. Ghika,et al.  Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group. , 1997, Clinical neuropharmacology.

[49]  J. Nutt,et al.  Short‐ and long‐duration responses to levodopa during the first year of levodopa therapy , 1997, Annals of neurology.

[50]  C. Marsden,et al.  The long-duration action of levodopa may be due to a postsynaptic effect. , 1997, Clinical neuropharmacology.

[51]  J. Nutt,et al.  Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[52]  T. Chase,et al.  Levodopa therapy , 1998, Neurology.

[53]  Y. Agid,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[54]  J. Dingemanse Issues important for rational COMT inhibition. , 2000, Neurology.

[55]  J. Hubble,et al.  Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[56]  J. Nutt Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. , 2000, Neurology.

[57]  D. Brooks,et al.  The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[58]  M. Contin,et al.  Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic–Dynamic Approach , 2001, Therapeutic drug monitoring.

[59]  R. Djaldetti,et al.  The Pharmacokinetic Profile of the “First Ever” Oral Dose of Levodopa in De Novo Patients with Parkinson's Disease , 2001, Clinical neuropharmacology.

[60]  J. Nutt,et al.  The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease , 2001, Clinical neuropharmacology.

[61]  Y. Agid,et al.  Dual-release formulation, a novel principle in l-dopa treatment of Parkinson’s disease , 2001, Neurology.

[62]  K. Leenders,et al.  Levodopa pharmacokinetic‐pharmacodynamic modeling and 6‐[18F]levodopa positron emission tomography in patients with Parkinson's disease , 2001, Clinical pharmacology and therapeutics.

[63]  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. , 2002, British journal of clinical pharmacology.

[64]  J. Nutt,et al.  Evolution of the response to levodopa during the first 4 years of therapy , 2002, Annals of neurology.

[65]  R. Hauser,et al.  Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[66]  Nicolas Simon,et al.  The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease. , 2004, Parkinsonism & related disorders.

[67]  A. Illi,et al.  Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease , 2004, European Journal of Clinical Pharmacology.